

**Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up**

<b>Rs. Mio.</b>	<b>Q2 17-18</b>	<b>Q2 16-17</b>	<b>% Gr y-y</b>	<b>YTD 17-18</b>	<b>YTD 16-17</b>	<b>% Gr y-y</b>
<b>Formulations Business - Key Markets</b>	<b>27,364</b>	<b>19,883</b>	<b>37.6%</b>	<b>45,125</b>	<b>38,091</b>	<b>18.5%</b>
US Formulations	16,436	9,888	66.2%	26,086	18,371	42.0%
India Formulations	8,945	8,209	9.0%	15,318	16,071	-4.7%
Latin America Formulations	675	656	2.8%	1,184	1,183	0.0%
Emerging Markets Formulations	1,309	1,130	15.9%	2,537	2,466	2.9%
<b>Other Businesses and Alliances</b>	<b>4,185</b>	<b>3,985</b>	<b>5.0%</b>	<b>8,096</b>	<b>8,401</b>	<b>-3.6%</b>
Europe Formulations	544	557	-2.3%	1,152	1,349	-14.6%
Consumer Wellness	1,198	1,119	7.1%	2,345	2,280	2.8%
Animal Health & Others	1,276	1,225	4.2%	2,333	2,322	0.5%
APIs	929	832	11.7%	1,619	1,808	-10.5%
Alliances	237	252	-5.9%	648	642	0.9%
<b>Grand Total</b>	<b>31,549</b>	<b>23,868</b>	<b>32.2%</b>	<b>53,221</b>	<b>46,491</b>	<b>14.5%</b>

Cadila Healthcare Ltd.

**Details of other incomes**

Rs. Mio.	Q2 17-18	Q2 16-17	% Gr y-y	YTD 17-18	YTD 16-17	% Gr y-y
<b>Other Operating Income</b>	<b>791</b>	<b>168</b>	<b>369.5%</b>	<b>1,407</b>	<b>875</b>	<b>60.7%</b>
Export Incentive	399	180	121.3%	671	467	43.7%
Royalty Income	0	19	-98.3%	6	50	-88.8%
Net Gain on foreign currency transactions and translation (Refer Note below)	86	-144	159.5%	86	87	-1.0%
Others	306	113	170.6%	644	272	137.0%

Note : There was a net gain of Rs. 136 Mio. on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods and a net gain of Rs. 23 Mio. included in other operating expenses in Q2 17-18. Thus, on aggregate level, there was a gain of Rs. 245 Mio. on operating transactions (above EBIDTA line) in Q2 17-18 vs loss of Rs. 264 Mio. in Q2 16-17. See details below for more clarity.

Rs. Mio.	Q2 17-18	Q2 16-17	% Gr y-y	YTD 17-18	YTD 16-17	% Gr y-y
<b>Other Income</b>	<b>225</b>	<b>236</b>	<b>-4.6%</b>	<b>435</b>	<b>389</b>	<b>12.0%</b>
Interest & Dividend income	113	181	-37.6%	203	301	-32.5%
Profit on sale of investments	11	21	-48.6%	33	52	-37.2%
Others	102	35	192.1%	199	36	458.1%

**Details of Foreign Exchange Fluctuations**

Rs. Mio. (+ = loss, - = gain)	Q2 17-18	Q2 16-17	% Gr y-y	YTD 17-18	YTD 16-17	% Gr y-y
<b>A. On operating transactions (above EBIDTA line)</b>	<b>-245</b>	<b>264</b>	<b>-192.8%</b>	<b>-228</b>	<b>-204</b>	<b>-11.8%</b>
a. Included in other income	-86	144	-159.7%	-86	-87	1.1%
b. Included in cost of goods	-136	120	-213.3%	-142	-117	-21.4%
c. Included in other expenses	-23					
<b>B. On Foreign Currency Borrowings (part of interest cost)</b>	<b>110</b>	<b>19</b>	<b>478.9%</b>	<b>86</b>	<b>37</b>	<b>132.4%</b>
<b>Total Foreign Currency Fluctuations (+ = loss, - = gain)</b>	<b>-135</b>	<b>283</b>	<b>-147.7%</b>	<b>-142</b>	<b>-167</b>	<b>15.0%</b>

**Details of R&D Expenses**

Rs. Mio.	Q2 17-18	Q2 16-17	% Gr y-y	YTD 17-18	YTD 16-17	% Gr y-y
<b>Total R&amp;D Expenses</b>	<b>2,757</b>	<b>1,529</b>	<b>80.3%</b>	<b>4,795</b>	<b>3,149</b>	<b>52.3%</b>

Consolidated Capex for H1 FY18

Rs. 5094  
Mio.

R&D capex included in above for H1 FY18

Rs. 210  
Mio.